Neurimmune develops drug candidates for diseases of the central nervous system (CNS) and related amyloid diseases.These include Alzheimer's disease, Parkinson's diseases, ALS, cardiomyopathy and type-2 diabetes. Neurimmune's clinical and advanced pre-clinical pipeline comprises human antibodies discovered by our Reverse Translational Medicine technology and one small molecule. Neurimmune’s earlier stage pipeline is focused on additional treatment modalities including vectorized human antibodies.

Download PDF

Therapeutic AreaIndicationTargetPartnerProduct CandidateHit selectionLead selectionPreclinicalPhase 1Phase 2Phase 3
CNS Alzheimer's Disease abeta Biogen Aducanumab*            
CNS Parkinson's Disease α-syn Biogen BIIB054**            
CNS Alzheimer's Disease tau Biogen BIIB076**            
CNS Dementia with Lewy Bodies / AD mAChR   NI004 / NSC001            
CNS Amyotrophic Lateral Sclerosis SOD1 TVM / Lilly NI005 / AP-101            
Cardiology ATTR Cardiomyopathy ATTR   NI006            
CNS Frontotemporal Dementia / ALS C9orf72 Biogen NI308*            
CNS Stroke / Spinal Cord Injury Nogo-A   hmAb            
Metabolic Type-2 Diabetes IAPP   NI203            
CNS Huntington's Disease HTT   NI302            
CNS Progresse Multifocal Leukoencephalopathy JCV   NI307            
CNS Frontotemporal Dementia / ALS TDP43 Biogen NI205**            
CNS Neurodegeneration   Ono NI504*            
CNS Tauopathies / AD tau REGENXBIO AAV hmAb            
      * licensed  ** acquired